A 93-year-old diabetic patient was prescribed sitafloxacin (100 mg, bid, po) for 8 days to treat a pulmonary infection. Prior to the treatment with sitafloxacin, his blood sugar was well controlled, but during treatment, his blood sugar showed abnormal biphasic dysregulation, with a downward trend in the early stages of treatment (d1-3) and an upward trend in the late stages of treatment (d4-8), and the dysglycemia persisted for about 20 days after treatment. Sitafloxacin, like other fluoroquinolones, may be strongly linked to glucose homeostasis abnormalities in this case, necessitating clinical medical staff vigilance, particularly in patients with high-risk diabetes.

No abstract